More importantly, in pancreatic cancer, oncolytic peptide LTX-315 promotes anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis which is dependent of CMTM6-mediated lysosomal degradation (Tang et al., 2022). This evidence concerns the gene CD274 and pancreatic neoplasm.